Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Genetics in Medicine

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/GIM.0b013e3181bb05bbPMID 19745746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular , Pulmonary and Renal Pathology Myofilament Degradation and Dysfunction of Human Cardiomyocytes in Fabry Disease

  2010cited by this paper
• Agalsidase alfa and kidney dysfunction in Fabry disease.

  2009cited by this paper
• Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events: Natural History Data From the Fabry Registry

  2009cited by this paper
• Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment

  2009cited by this paper
• Natural course of Fabry disease: changing pattern of causes of death in FOS – Fabry Outcome Survey

  2009cited by this paper
• Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry

  2008cited by this paper
• Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

  2008cited by this paper
• Angiokeratoma corporis diffusum.

  2008cited by this paper
• Cardiovascular disease and subsequent kidney disease.

  2007cited by this paper
• Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

  2007cited by this paper
• Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life

  2007cited by this paper
• Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy.

  2007cited by this paper
• Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

  2007cited by this paper
• The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels

  2007cited by this paper
• Agalsidase-Beta Therapy for Advanced Fabry Disease

  2007cited by this paper
• Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement

  2006cited by this paper
• Deaths: final data for 2003.

  2006cited by this paper
• Pediatric Fabry Disease

  2005cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., Valle, D., Childs, B., Kinzler, K. W., and Vogelstein, B., eds., 8th ed., McGraw-Hill, New-York, 2001, 7012 p., $550.00)

  2004cited by this paper
• Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

  2004cited by this paper
• Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey

  2004cited by this paper
• Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

  2004cited by this paper
• The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents

  2003cited by this paper
• Natural History of Fabry Renal Disease: Influence of α-Galactosidase A Activity and Genetic Mutations on Clinical Course

  2002cited by this paper
• Inflammation and cardiovascular risk in dialysis patients.

  2002cited by this paper
• Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy

  2002cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

  2001cited by this paper
• Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

  2001cited by this paper
• A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

  2001cited by this paper
• Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

  2001cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease

  2001cited by this paper
• α-Galactosidase A deficiency. Fabry disease

  2001cited by this paper
• Cardiovascular disease after renal transplantation.

  2000cited by this paper
• Prevalence of lysosomal storage disorders.

  1999cited by this paper
• Statistical Analysis of Epidemiologic Data

  1993cited by this paper
• Angiokeratoma corporis diffusum--Fabry's disease.

  1967cited by this paper
• Angiokeratoma corporis diffusum. A clinical study of eight affected families.

  1962cited by this paper
• ANGIOKERATOMA CORPORIS DIFFUSUM.

  1955cited by this paper

• Endothelial dysfunction in Fabry disease: retinal biomarkers link cardiac GLA gene variants with chronic inflammation

  2026cites this paper
• Fabry Disease Beyond Storage: The Role of Inflammation in Disease Progression

  2025cites this paper
• Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centre

  2025cites this paper
• Expert review in diagnostic, therapeutic and follow-up of Fabry disease in Latin America based on patient care standards

  2025cites this paper
• Prevalence and Clinical Correlates of Cerebrovascular Alterations in Fabry Disease: A Cross-Sectional Study

  2025cites this paper
• Disrupted synaptic gene expression in Fabry disease: Findings from RNA sequencing.

  2025cites this paper
• Historical Control Analysis Demonstrates Greater Long‐Term Reduction in Plasma Globotriaosylceramide (Gb3) by Venglustat Compared With Placebo or Agalsidase Beta in Male Patients With Classic Fabry Disease

  2025cites this paper
• Fabry disease in females: organ involvement and clinical outcomes compared with the general population

  2025influential citation
• [A little bit about sphingolipidoses in cardiology: a clinical case of Fabry disease].

  2025cites this paper
• Telomere Length, Oxidative Stress, and Kidney Damage Biomarkers in Fabry Nephropathy

  2025cites this paper
• Long-term efficacy of migalastat in females with Fabry disease

  2025cites this paper
• Unraveling the Hidden Burden of Gastrointestinal and Nutritional Challenges in Children with Fabry Disease: A Systematic Review with Meta-Analysis

  2025cites this paper
• New Drugs Available for Fabry Disease

  2025cites this paper
• Cardiac involvement in Fabry disease: Implications of retinal vessel analysis in detecting early microvascular alterations despite ERT

  2025cites this paper
• Early diagnosis of cardiac involvement in Anderson-Fabry disease using cardiac MRI parameters.

  2025cites this paper
• Risk factors, stroke rates and aspirin prescribing trends in the Canadian Fabry disease initiative cohort

  2025cites this paper
• Long‐term effectiveness and safety outcomes in adults with Fabry disease treated with agalsidase alfa: 20 years of data from the Fabry Outcome Survey

  2025cites this paper
• Axon guidance deficits in a human sensory neuron model of Fabry disease

  2025cites this paper
• Females with Fabry disease: an expert opinion on diagnosis, clinical management, current challenges and unmet needs

  2025cites this paper
• Cardiac magnetic resonance imaging in the follow-up of patients with Fabry cardiomyopathy.

  2025cites this paper
• “Real world” medical care of patients with Fabry disease by primary care physicians, internists or general practitioners

  2025cites this paper
• Cardiac Magnetic Resonance Imaging in the Evaluation and Prognosis of Infiltrative Cardiomyopathies

  2025cites this paper
• Left ventricular myocardial work combined with stress echocardiography assessment of cardiac function in patients with Fabry disease

  2025cites this paper
• A multi-country time and motion study to describe the experience and burden associated with the treatment of Fabry disease with enzyme replacement therapy with agalsidase alfa and agalsidase beta

  2025cites this paper
• Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy

  2025cites this paper
• Inner retinal hyper-reflective foci number correlates with flood-illumination adaptive optics ophthalmoscopy grading and systemic organ involvement in patients with Fabry disease

  2025cites this paper
• Correlation of enzyme activities and genotype with clinical manifestations in Chinese patients of different sexes with classical and late-onset Fabry disease

  2025cites this paper
• The use and performance of lyso-Gb3 for the diagnosis and monitoring of Fabry disease: A systematic literature review.

  2025cites this paper
• Treatment Beliefs Reflect Unmet Clinical Needs in Lysosomal Storage Diseases: An Opportunity for a Patient‐Centered Approach

  2025cites this paper
• A systematic literature review to evaluate the cardiac and cerebrovascular outcomes of patients with Fabry disease treated with agalsidase Beta

  2025cites this paper
• Urine-derived renal epithelial cells for deep phenotyping and transcriptomic response to therapy in Fabry disease

  2025influential citation
• A composite measurement concept for monitoring cardiac function in Fabry disease

  2025influential citation
• Fabry disease in women: beyond the role of “carriers”

  2025cites this paper
• The Identification of a Novel Pathogenic Variant of the GLA Gene Associated with a Classic Phenotype of Anderson–Fabry Disease: A Clinical and Molecular Study

  2025cites this paper
• Complement System and Adhesion Molecule Skirmishes in Fabry Disease: Insights into Pathogenesis and Disease Mechanisms

  2024cites this paper
• Preclinical efficacy and safety of adeno-associated virus 5 alpha-galactosidase: A gene therapy for Fabry disease

  2024cites this paper
• Anderson–Fabry Disease: Focus on Ophthalmological Implications

  2024cites this paper
• Biomarker testing for lysosomal diseases: A technical standard of the American College of Medical Genetics and Genomics (ACMG).

  2024cites this paper
• Different diseases, different needs: Patient preferences for gene therapy in lysosomal storage disorders, a probabilistic threshold technique survey

  2024cites this paper
• Infrared spectroscopy as a new approach for early fabry disease screening: a pilot study

  2024cites this paper
• Impact of Nontreatment Duration and Keratopathy on Major Adverse Cardiovascular Events in Fabry Disease: A Nationwide Cohort Study

  2024cites this paper
• Top 10 Clinical Pearls in Inherited Neuropathies

  2024cites this paper
• 2024 Update of the TSOC Expert Consensus of Fabry Disease.

  2024cites this paper
• Characterization of the Plasma Proteomic Profile of Fabry Disease: Potential Sex- and Clinical Phenotype-specific Biomarkers.

  2024cites this paper
• Dynamics of Leukocyte Telomere Length in Patients with Fabry Disease

  2024cites this paper
• Renal and multisystem effectiveness of 3.9 years of migalastat in a global real‐world cohort: Results from the followME Fabry Pathfinders registry

  2024cites this paper
• Agalsidase alfa long-term effect on left ventricular hypertrophy in Fabry disease.

  2024cites this paper
• Caseous Calcification of the Mitral Annulus

  2024cites this paper
• Ventricular arrhythmias and primary prevention of sudden cardiac death in Anderson-Fabry disease.

  2024cites this paper
• Inflammatory and Cardiovascular Biomarkers to Monitor Fabry Disease Progression

  2024cites this paper
• Fabry disease phenotyping in women from the complete Romanian cohort – time for early diagnostic awareness

  2024cites this paper
• Right heart and left atrial strain to differentiate cardiac amyloidosis and Fabry disease

  2024cites this paper
• Anderson–Fabry Disease: Red Flags for Early Diagnosis of Cardiac Involvement

  2024cites this paper
• Frequency of Fabry disease in chronic kidney disease patients including patients on renal replacement therapy in Korea

  2024cites this paper
• Increased prevalence of peripheral vestibular disorder among patients with Fabry disease

  2024cites this paper
• Role of Longitudinal Strain in the Evaluation of Contractile Dysfunction in Japanese Fabry Disease Patients.

  2024cites this paper
• The underdiagnosed kidney burden of Fabry disease in females

  2024cites this paper
• Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

  2024cites this paper
• Society for Cardiovascular Magnetic Resonance 2023 Cases of SCMR case series

  2024cites this paper
• Rescue from sudden ventricular tachycardia and fibrillation using wearable cardioverter-defibrillator in male late-onset Fabry disease patient.

  2024cites this paper
• Clinical and CMR characteristics associated with cardiac events in patients with Fabry disease.

  2023cites this paper
• Magnitude of the Potential Screening Gap for Fabry Disease in Manitoba: A Population-Based Retrospective Cohort Study

  2023cites this paper
• Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community.

  2023cites this paper
• Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies

  2023cites this paper
• Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?

  2023cites this paper
• Management of Hypertension in Fabry Disease

  2023cites this paper
• Cardiac surgery of aortic valve and ascending aorta (Bentall procedure) in a patient with Fabry disease without enzyme replacement therapy: an overview of aortic and aortic valve surgical tips

  2023cites this paper
• Diagnosis and Treatment of Fabry Disease - A Review

  2023influential citation
• Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease

  2023cites this paper
• Cardiomyocyte Globotriaosylceramide Accumulation in Adult Male Patients with Fabry Disease and IVS4 + 919G>A GLA Mutation is Progressive with Age and Correlates with Left Ventricular Hypertrophy and Reduced Left Ventricular Ejection Fraction

  2023cites this paper
• Maladie de Fabry en cardiologie revue de la littérature et point de vue d’experts [Fabry disease in cardiology practice Literature review and expert point of view]

  2023cites this paper
• Difficulties in Diagnosing Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy (LVH): Is the Novel GLA Gene Mutation a Pathogenic Mutation or Polymorphism?

  2023cites this paper
• Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

  2023cites this paper
• [Cardiac imaging in infiltrative cardiomyopathies. What cardiovascular imaging modalities to propose in hypertrophic cardiomyopathies ?]

  2022cites this paper
• Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes

  2022cites this paper
• Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.

  2022cites this paper
• Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study.

  2022cites this paper
• Screening of Fabry disease in patients with an implanted permanent pacemaker.

  2022cites this paper
• Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective

  2022cites this paper
• An Overview of Molecular Mechanisms in Fabry Disease

  2022cites this paper
• A survey on the patient journey in Fabry disease in Japan

  2022cites this paper
• The Role of Multimodality Imaging in the Evaluation of Heart Failure with Preserved Ejection Fraction.

  2022cites this paper
• Emerging cellular themes in leukodystrophies

  2022cites this paper
• Autophagy-lysosome pathway alteration in ocular surface manifestations in Fabry disease patients

  2022cites this paper
• Metabolic Fingerprinting of Fabry Disease: Diagnostic and Prognostic Aspects

  2022cites this paper
• A Case of Fabry Disease with Central Retinal Artery Occlusion

  2022cites this paper
• Enfermedad de Fabry: un año en tratamiento con migalastat

  2022cites this paper
• Integrating Cardiac MRI Imaging and Multidisciplinary Clinical Care is associated with Improved Outcomes in Patients with Fabry Disease.: Improving clinical outcomes in patients with Fabry Disease.

  2022cites this paper
• Fabry Disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment

  2022cites this paper
• X-Linked Kidney Disorders in Women.

  2022cites this paper
• Early renal failure in childhood in a male with Fabry disease

  2022cites this paper
• The Cardiovascular Manifestations of Anderson-Fabry Disease

  2022cites this paper
• Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry

  2022cites this paper
• Ceria-Zirconia nanoparticles reduce intracellular globotriaosylceramide accumulation and attenuate kidney injury by enhancing the autophagy flux in cellular and animal models of Fabry disease

  2022cites this paper
• Role of Cardiac Magnetic Resonance in the Diagnosis of Infiltrative, Hypertrophic, and Arrhythmogenic Cardiomyopathies.

  2022cites this paper
• Sex‐Related Differences in Genetic Cardiomyopathies

  2022cites this paper
• The prevalence of Fabry disease in a statewide chronic kidney disease cohort – Outcomes of the aCQuiRE (Ckd.Qld fabRy Epidemiology) study

  2022cites this paper
• COVID-19 in Fabry disease: a reference center prospective study

  2022cites this paper
• Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience

  2022cites this paper
• Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation

  2022cites this paper